Overall impact
B (77)

Commentary

PetVivo is a strong overall performer. With a 'B' rating of 76.9 for overall impact (91st percentile compared to all companies), PetVivo ranks 10th out of 103 industry peers, behind Endologix, Biostage, RA Medical Systems and 6 others, and ahead of Waters, MyMD Pharmaceuticals, Alphatec and 90 others. On top material causes for PetVivo's industry (Healthcare Equipment), PetVivo performs well in Child and Maternal Health (81.9 score), Reduced Use of tobacco (86.3), Access to Affordable Healthcare (85.1) and 6 other causes where it received an 'A' score. PetVivo did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PETV
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
22
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Mn, United States
Share classes
PETV
Description
PetVivo Holdings, Inc. is a biomedical device company that manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
Material causes
Ethos considers the following causes material for PetVivo, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.